Results 101 to 110 of about 11,219 (248)

AChR deficiency due to ε-subunit mutations: Two common mutations in the Netherlands [PDF]

, 2009
Congenital myasthenic syndromes are a clinically and genetically heterogeneous group of hereditary disorders affecting neuromuscular transmission. We have identified mutations within the acetylcholine receptor (AChR) ε-subunit gene underlying congenital ...
Baets, M.H. (Marc) de, Beeson, D. (David), Bonifati, D.M. (Domenic), Doorn, P.A. (Pieter) van, Faber, C.G. (Carin), Kuks, J.B.M. (Jan), Molenaar, P.C. (Peter), Verschuuren, J.J. (Jan), Vles, J.S.H. (Johannes), Wokke, J.H.J. (John)   +9 more
core   +1 more source

The Effect of Thymectomy on the Incidence of Extrathymic Cancers and Autoimmune Diseases in Patients With Non‐Thymomatous Myasthenia Gravis

Muscle &Nerve, Volume 73, Issue 6, Page 1065-1072, June 2026.
ABSTRACT Introduction/Aims Thymectomy is associated with positive effects on myasthenia gravis (MG), but there is conflicting evidence regarding potential deleterious long‐term outcomes, such as increased cancer and autoimmune disease risk. We aimed to assess these outcomes in thymectomized versus non‐thymectomized MG patients.
Mohamed Khateb, Adnan Almasri, Carolina Barnett‐Tapia, Vera Bril   +3 more
wiley   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Myasthenia gravis complicated by Graves’ disease: a case report

Journal of Medical Case Reports
Introduction Myasthenia gravis is a neuromuscular autoimmune condition characterized by the presence of antibodies against acetylcholine receptors. It may present as a generalized disorder or remain limited to specific muscle groups.
Larrey Kasereka Kamabu, Ronald Oboth, Louange Maha Kataka, Albert Yemba Baruani, Hervé Monka Lekuya, Charles Kahindo Kangitsi   +5 more
doaj   +1 more source

Polymorphic myopathological findings in a 77‐year‐old woman with oculo‐bulbo‐facial and distal weakness

Brain Pathology, EarlyView.
Michele Tosi, Angela Puma, Elena Faedo, Gianmarco Severa, Luisa Villa, Sabrina Sacconi, Edoardo Malfatti   +6 more
wiley   +1 more source

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers

British Journal of Pharmacology, Volume 183, Issue 11, Page 2874-2889, June 2026.
Abstract Background and Purpose Overactivation of the alternative pathway (AP) underlies several diseases. Iptacopan is an oral, first‐in‐class, highly potent specific inhibitor of factor B, a key AP protease. Experimental Approach The analysis included data from two phase 1 randomised, volunteer‐blinded, placebo‐controlled studies: Study 1, a single ...
Irina Baltcheva, Guido Junge, Kenneth Kulmatycki, Robert Schmouder, Anna Schubart, Marie‐Anne Valentin   +5 more
wiley   +1 more source

Myasthenia gravis and preeclampsia: Dot all the I's and cross all the T's

Journal of Taibah University Medical Sciences, 2017
Although rare, the co-occurrence of myasthenia gravis and preeclampsia during pregnancy is responsible for considerable maternal and foetal morbidity and mortality.
Ali Hassan, FCPS
doaj   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, Volume 13, Issue 5, Page 1028-1040, May 2026.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Miasthenia gravis in pediatric age

Acta Médica del Centro, 2008
Background: Myasthenia gravis is an autoimmune disorder characterized by fluctuating muscle weakness and fatigue of different muscle groups, secondary to a synaptic transmission alteration caused by the blockade and destruction of the acetylcholine ...
Liubka María Pérez Mederos, María Ofelia Hernández Oliver, Cecilio González Benavides, José Manuel González Santos   +3 more
doaj  

Therapeutic gymnastics in comprehensive treatment of patients with generalized myasthenia [PDF]

The technique of therapeutic gymnastics was used for patients with mayasthenia gravis to control the consequences of hypodynamia induced by the myasthenic process.
Kapelovich, R. L.
core   +1 more source